101 results about "Pseudoephedrine" patented technology

A dosage form containing cetirizine as an immediate release component and pseudoephedrine or a pharmaceutically acceptable salt thereof as a controlled release component. A portion of the pseudoephedrine can also be incorporated as an immediate release component. The dosage form is free of alcohols having a molecular weight lower than 100 and reactive derivatives thereof.

The present invention provides for devices and methods for vending regulated products, particularly controlled substances, including those containing pseudoephedrine. The present invention allows for the identification of consumers through reliable log-in-procedures, allows the consumer to select items, validates whether the purchase request complies with regulations, to facilitate the delivery of the requested product to a consumer. Other embodiments include a vending machine that is placed into a retail environment in which software enforces validation of the purchasers' identities, limits the amount of pseudoephedrine for each purchaser within the regulations of local, state and federal agencies.

This invention reduces the resources which must be expended in retail locations to comply with regulatory agencies, to implement effective counter measures against illegal purchases of regulated and controlled substances, and to ensure the effective limitation of these substances within reasonable limits required for normal consumption.

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

The invention relates to an action of ferulic acid on enhancing the drug effect of some medicaments and a purpose thereof, wherein the medicaments mainly comprise alkaloid medicaments including matrine, kushenin, sophocarpine, hyoscyamine, narceine, hanfangchin A, jamaicin, morphine, codeine, evodiamine, strychnine, catharanthine, vincristine, taxol, verticine, peimine, peiminine, ephedrine, pseudoephedrine, wilfordine, triptolide, tripdiolide and the like, and flavonoid medicaments including puerarin, ginsenoside, ginsengenin, mangiferin, scutelloside, alkannin, meletin, rutin, hesperidin, daidzin, soybean isoflavone, daidzein, carthamin, catechin and the like. The ferulic acid and the medicaments can form a compound or a medicament compound, or the ferulic acid and the medicaments can generate a chemical reaction (including salification, esterification, amidation, ketonization, etherification and the like), and/or the ferulic acid and the medicaments can generate a synergistic effect and an additive effect.

The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.

A tamper resistant drug delivery system made of at least one lipid, at least one gelling agent and at least one sympathomimetic amine, such as for example pseudoephedrine, wherein the system gels in the presence of water or a solution containing water and ethanol, wherein the sympathomimetic amine releases into the digestive system when ingested, and wherein the weight ratio of gelling agent to lipid is less than 1:1.4.

In an effort to control the production of illegal drugs such as methamphetamine, new statutes have placed restrictions on the sale of common cold remedies that contain pseudoephedrine and other precursors used in the production of these illegal drugs. Many common products, such as Sudafed® cold medicine, have been removed from store shelves and are now behind the counter at most pharmacies. These legal restrictions vary from state to state, but most restrict the amount of product that can be purchased by quantity and time. These legal restrictions also require creation of a customer log that often includes the customer's name, address, government-issued photo identification number and/or signature. Clearance of these restricted product sales and creation of the customer log are time consuming tasks that result in long lines during the winter season. The present invention is an automated process to speed up the authorization process and creation of the customer logs. The process can be applied to a single store or multiple stores. The invention also includes a clearance terminal especially adapted for this process.

Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations.

The invention discloses a hapten and a complete antigen which are used for methamphetamine detection and antibody preparation. The invention also discloses an anti-methamphetamine monoclonal antibody prepared from the complete antigen, and a colloidal gold marked methamphetamine monoclonal antibody immunoassay plate, which are used for detecting the methamphetamine in pharmaceutical products and human specimens of urine samples and the like. Compared with chromatographic processes of HPLC and the like, the immunoassay plate is simple and portable and is easy to carry, can perform field detection, and needs no expensive devices. By using the immunoassay plate to detect the methamphetamine, the entire test can be finished in 3 to 5 minutes, the detection sensitivity can reach 300 ng, and the immunoassay plate has no cross-reactions with 60 common medicaments and poisons, in particular ephedrine and pseudoephedrine.

A method for identifying whether ephedrine and/or pseudo ephedrine are/is added to weight-reducing type traditional Chinese medicine or health care products rapidly identifies whether illicit ephedrine and/or pseudo ephedrine are/is added to weight-reducing type traditional Chinese medicine preparations or health care food through a two-dimensional correlation infrared spectroscopy method and includes the following steps of preparing potassium bromide tablets, collecting a dynamic spectrum, obtaining characteristic peaks, conducting comparison and judgment to determine whether a to-be-tested sample contains ephedrine and/or pseudo ephedrine, wherein two-dimensional correlation spectra of the obtained to-be-tested sample, an ephedrine standard sample and a pseudo ephedrine standard sample are compared and judged, and characteristic peaks, correlation peaks and cross peaks are sequentially contrasted for a two-dimensional correlation power spectrum, a two-dimensional correlation synchronous spectrum and a two-dimensional correlation asynchronous spectrum.

A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process.

An oral disintegrating tablet of dextromethorphan for treating the cold caused cough, nasal congestion and rhinorrhea is proportionally prepared from dextromethorphan, chlorphenamine, pseudoephedrine, beta-cyclodextrin or ion exchange resin, mannitol or lactose starch, and disintegrant through sieving, flavouring, mixing and die pressing.

The present invention provides immunoassays which are highly specific for detection in biological samples of methamphetamine and other drugs of abuse of the methamphetamine group such as ecstasy and other ecstasy class drugs. More particularly, competitive assays are provided comprising: (a) contacting said sample with (i) a pseudoephedrine/carrier conjugate in which pseudoephedrine is linked via its hydroxyl group to the carrier and (ii) an antibody which is capable of binding both one or more drugs of the methamphetamine group and said conjugate; and (b) determining whether the binding of said antibody to said conjugate is reduced by the presence of said sample, a reduction in binding being indicative that the sample contains a methamphetamine group drug.

The invention discloses a preparation method for an ephedrine or pseudoephedrine intermediate. The preparation method comprises the following steps: with 2-chloropropionyl chloride and benzene as starting materials, carrying out the Friedel-Crafts reaction under the catalysis of Lewis acid so as to produce 2-chloro-1-phenyl-1-acetone; and reacting produced 2-chloro-1-phenyl-1-acetone with methylamine in an aprotic solvent so as to produce 2-methylamino-1-phenyl-1-acetone. The invention also discloses a preparation method for ephedrine or pseudoephedrine. According to the methods, phosphorus trichloride with severe pollution is not used anymore, and dangerous and expensive bromine is not used any longer; the Friedel-Crafts reaction and methylamination are carried out in the same solvent, so cost for public works is saved; and a safe, simple, cheap, green and novel process is provided for synthesis of ephedrine and pseudoephedrine.

The invention relates to a sustained release preparation taking glyceryl guaiacolate and pseudoephedrine or physiologically acceptable salts thereof as active components, and provides a compound preparation which can overcome cold related symptoms and of which all the active components are slowly released.

The invention relates to a chemical method for synthesizing ephedrine. In the technology, (+/-)alpha-methylaminophenylpropanone hydrochloride is taken as a raw material and reduced to the mixtures of (+/-)ephedrine and (+/-)pseudoephedrine by a proper reducing agent; the (+/-)ephedrine is separated, and the l-ephedrine or l-ephedrine hydrochloride is separated by using chiral organic acid as a resolving agent. The method enjoys simple technology, less equipment investment, less environment pollution, less hazardous and poisonous chemical reagents which are used and the like.

In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.

The invention discloses a sustained release compound capsules and its preparation method, wherein each capsule comprises a desloratadine tablet and a plurality of pseudo ephedrine slow release particles, the active components include desloratadine 2.5mg-5mg, pseudo ephedrine 120mg-240mg. The compound slow release capsule can increase the biological availability and compliableness for the patients.

In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.

The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations.

The invention discloses a medicine composition for treating flu and a preparation method thereof. The medicine composition is mainly prepared from glycyrrhizic acid, baicalin, pseudoephedrine, taurine and other compounds. The invention has the advantages of simple medicine composition and exact curative effect; and animal experiments indicate that the medicine composition has strong inhibiting effect on influenza A virus and influenza B virus, and has the effects of killing various respiratory tract pathogenic bacteria to different degrees. The medicine composition has obvious and long-lasting antipyretic action and obviously relieves various cold symptoms, such as rhinorrhoea, snuffle, pains, cough and the like. The medicine composition has the action of synergy, can address both the symptoms and root causes against the causes and the symptoms of cold, and can obviously shorten the course of cold. The medicine composition can be made into any acceptable excipient in pharmaceutics.